Tricyclic heterocycles as FGFR inhibitors
US11939331B2 · kind B2 · utility
2Cited by
71References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 8, 2022 |
| Grant date | Mar 26, 2024 |
| Priority date | — |
| Expiry date | Jun 8, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.